RT Journal Article
SR Electronic
T1 Private prescribing of controlled opioids in England, 2014-2021: a retrospective observational study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.24.23286407
DO 10.1101/2023.02.24.23286407
A1 Martus, Isabella
A1 MacKenna, Brian
A1 Rial, William
A1 Hayhurst, Jon
A1 Richards, Georgia C.
YR 2023
UL http://medrxiv.org/content/early/2023/03/13/2023.02.24.23286407.abstract
AB Background Trends of opioid prescribing in the NHS has been well published, yet trends for the same in private prescribing have not been widely established.Aim To assess trends and geographical variation of controlled opioids prescribed by private prescribers in England.Design and setting A retrospective observational study in English primary healthcare.Methods Data on Schedule 2 and 3 controlled opioids (“controlled opioids”) was obtained from the NHS Business Services Authority (BSA) using freedom of information (FOI) requests between 01 January 2014 and 30 November 2021. Absolute counts and rates of the number of items dispensed per cumulative number of registered private prescribers were calculated and stratified over time, by opioid type, and geographical region.Results 128,341 items controlled opioids were prescribed by private prescribers in England between January 2014 and November 2021, which decreased by 50% from 23,339 items (4.09 items/prescriber) in 2014 to 11,573 items (1.49 items/prescriber) in 2020. Methadone (36%) was the most common controlled opioid prescribed privately, followed by morphine (18%), buprenorphine (16%), and oxycodone (12%). Prescriptions were highest in London (74%), followed by the South-East of England (7%). A proportion of items (n=462, 0.35%) were prescribed by “unidentified doctors” where the prescription is not readily attributable to an individual prescriber by the BSA.Conclusions Controlled opioids prescribed by private prescribers in England decreased and were primarily prescribed in London. To ensure patient safety, the monitoring and surveillance of controlled opioids dispensed privately should continue and items linked to “unidentified doctors” should be addressed further.How this fits in There are concerns over the long-term, high-dose use of opioids in people with chronic pain – trends for which have been described using English NHS prescription data. However, opioids can also be acquired from outside of NHS services, including private prescribers, over-the-counter (e.g. co-codamol), and through online healthcare services and pharmacies or the “dark web”. Without exploring non-NHS data, the full picture of opioid use in England cannot be understood. This study sought to fill this gap by investigating opioids in the private sector. We found that the number of controlled opioid items prescribed by private prescribers in England halved between January 2014 and November 2021, and that most prescribing occurred from prescribers in London. There were also controlled opioid items dispensed by “unidentified doctors”, which must be addressed to ensure patient safety. While there is monitoring of controlled drug prescribing by NHS England Controlled Drug Accountable Officers, expanding access to such data to allow for a greater visibility and wider analysis of non-NHS data, including the private prescribing of controlled opioids, will allow policymakers and clinicians to further assess the implementation of pain guidelines and identify harms that can be addressed to improve patient safety.Competing Interest StatementIEM and JH has no competing interests to declare. BMK declares that in addition to his role at the Bennett Instititue, BMK is employed by NHS England as a specialist pharmacist. All past declarations for BMK are openly available at https://www.whopaysthisdoctor.org/doctor/491/active. WR is employed by NHS England as a Regional Chief Pharmacist in the East of England and the national lead for the Controlled Drugs Accountable Officer function. GCR is the Director of a limited company that is independently contracted to work as an Epidemiologist and teach at the University of Oxford. GCR received scholarships from NIHR SPCR, the Naji Foundation, and the Rotary Foundation between 2017-2021 to study for a Doctor of Philosophy (DPhil/PhD).Clinical Protocols https://doi.org/10.17605/OSF.IO/HCKPU Funding StatementNo funding was obtained for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll study materials and data is openly available via online repositories (https://doi.org/10.17605/OSF.IO/HFKDQ(27). The study protocol was preregistered on the Open Science Framework (https://doi.org/10.17605/OSF.IO/HCKPU)(21). Data were obtained from the NHSBSA through freedom of information requests; ePACT2, NHSBSA Copyright 2022. This information is licensed under the terms of the Open Government Licence. https://doi.org/10.17605/OSF.IO/HFKDQ